Literature DB >> 33222013

Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer.

Siyuan Hao1, Jiayi Liu1, Jia Ma2.   

Abstract

We have read the article by Cai et al. and find there is a discrepancy between their data and conclusion. Their statement, "Specifically, DSG2 expression was associated with tumor size", is not supported by their own clinicopathological data and analysis. After reviewing some similar articles, we also found no available evidence showed a statistically significant association between them. Therefore, we would like to suggest Cai et al. to rectify the results they published.

Entities:  

Keywords:  Clinicopathological features; Desmoglein 2; Non-small-cell lung cancer

Year:  2020        PMID: 33222013     DOI: 10.1007/s00432-020-03465-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2.

Authors:  Feng Cai; Qingqing Zhu; Yingying Miao; Simei Shen; Xin Su; Yi Shi
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-14       Impact factor: 4.553

2.  Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.

Authors:  Yanyu Bi; Yiming Jiang; Xia Li; Guoxin Hou; Kesang Li
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-23       Impact factor: 4.553

3.  Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost.

Authors:  Tian-Qi Du; Xiang Li; Wei-Si Zhong; Jian-Dong Tian; Yu-Xia Zhao; Dan Liu
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-26       Impact factor: 4.553

4.  Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.

Authors:  Kosuke Kashiwabara; Shinji Fujii; Shinsuke Tsumura; Kazuhiko Sakamoto
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-06       Impact factor: 4.553

5.  Desmoglein-2 overexpression predicts poor prognosis in hepatocellular carcinoma patients.

Authors:  C-P Han; Y-H Yu; A-G Wang; Y Tian; H-T Zhang; Z-M Zheng; Y-S Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-09       Impact factor: 3.507

6.  Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.

Authors:  Runsen Jin; Xinfeng Wang; Ruochuan Zang; Chengming Liu; Sufei Zheng; Hecheng Li; Nan Sun; Jie He
Journal:  Cancer Lett       Date:  2020-04-07       Impact factor: 8.679

7.  Eight potential biomarkers for distinguishing between lung adenocarcinoma and squamous cell carcinoma.

Authors:  Jian Xiao; Xiaoxiao Lu; Xi Chen; Yong Zou; Aibin Liu; Wei Li; Bixiu He; Shuya He; Qiong Chen
Journal:  Oncotarget       Date:  2017-05-03
View more
  1 in total

1.  The prognostic and clinicopathological significance of desmoglein 2 in human cancers: a systematic review and meta-analysis.

Authors:  Jiantao Wang; Siyuan Hao; Junjie Gu; Sean G Rudd; Yan Wang
Journal:  PeerJ       Date:  2022-03-22       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.